Patents by Inventor Nelson L. MICHAEL

Nelson L. MICHAEL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following ZIKV infection or vaccination
    Patent number: 11884718
    Abstract: The invention described herein provides antibodies to Zika virus. The novel polypeptides are useful alone or as portions of larger molecules, such as antibodies or antibody fragments, that can be used to treat or prevent infection of Zika virus.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: January 30, 2024
    Assignees: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Beth Israeli Deaconess Medical Center, Inc., The Government Of The United States As Represented By The Secretary Of The Army
    Inventors: Shelly Krebs, Gina Donofrio, Vincent Dussupt, Kayvon Modjarrad, Dan Barouch, Richard G. Jarman, III, Nelson L. Michael, Gordon Joyce, Rajeshwer Singh Sankhala, Kathryn Elaine Stephenson
  • Potent Zika Virus-Specific and Cross-Neutralizing Monoclonal Antibodies to Zika and Dengue Viruses Following Zikv Infection or Vaccination
    Publication number: 20210238262
    Abstract: The invention described herein provides antibodies to Zika virus. The novel polypeptides are useful alone or as portions of larger molecules, such as antibodies or antibody fragments, that can be used to treat or prevent infection of Zika virus.
    Type: Application
    Filed: April 24, 2019
    Publication date: August 5, 2021
    Applicants: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Beth Israel Deaconess Medical Center, Inc., The Government of the United States as Represented by the Secretary of the Army
    Inventors: Shelly Krebs, Gina Donofrio, Vincent Dussupt, Kayvon Modjarrad, Dan Barouch, Richard G. Jarman, III, Nelson L. Michael, Gordon Joyce
  • Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
    Patent number: 10525123
    Abstract: Methods for inducing an immune response against Human Immunodeficiency Virus (HIV) in HIV-infected subjects undergoing antiretroviral therapy (ART) are described. The methods include administering an adenovirus vector primer vaccine and a modified vaccinia virus (MVA) vector booster vaccine encoding mosaic HIV antigens.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: January 7, 2020
    Assignees: Janssen Vaccines & Prevention B.V., Beth Israel Deaconess Medical Center, Inc., THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC., The Government of The United States, as represented by The Secretary Of The Army
    Inventors: Frank Tomaka, Maria Grazia Pau, Johanna Schuitemaker, Dan Barouch, Jintanat Ananworanich, Merlin Robb, Nelson L. Michael, Jerome Kim
  • METHODS FOR INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDERGOING ANTIRETROVIRAL TREATMENT
    Publication number: 20190247491
    Abstract: Methods for inducing an immune response against Human Immunodeficiency Virus (HIV) in HIV-infected subjects undergoing antiretroviral therapy (ART) are described. The methods include administering an adenovirus vector primer vaccine and a modified vaccinia virus (MVA) vector booster vaccine encoding mosaic HIV antigens.
    Type: Application
    Filed: April 16, 2019
    Publication date: August 15, 2019
    Inventors: Frank TOMAKA, Maria Grazia PAU, Johanna SCHUITEMAKER, Dan BAROUCH, Jintanat ANANWORANICH, Merlin ROBB, Nelson L. MICHAEL, Jerome KIM
  • Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
    Patent number: 10307477
    Abstract: Methods for inducing an immune response against Human Immunodeficiency Virus (HIV) in HIV-infected subjects undergoing antiretroviral therapy (ART) are described. The methods include administering an adenovirus vector primer vaccine and a modified vaccinia virus (MVA) vector booster vaccine encoding mosaic HIV antigens.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: June 4, 2019
    Assignees: Janssen Vaccines & Prevention B.V., The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Beth Israel Deaconess Medical Center, Inc., The United States of America, as represented by The Secretary Of The Army
    Inventors: Frank Tomaka, Maria Grazia Pau, Johanna Schuitemaker, Dan Barouch, Jintanat Ananworanich, Merlin Robb, Nelson L. Michael, Jerome Kim
  • METHODS FOR INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDERGOING ANTIRETROVIRAL TREATMENT
    Publication number: 20180064803
    Abstract: Methods for inducing an immune response against Human Immunodeficiency Virus (HIV) in HIV-infected subjects undergoing antiretroviral therapy (ART) are described. The methods include administering an adenovirus vector primer vaccine and a modified vaccinia virus (MVA) vector booster vaccine encoding mosaic HIV antigens.
    Type: Application
    Filed: September 1, 2017
    Publication date: March 8, 2018
    Inventors: Frank TOMAKA, Maria Grazia PAU, Johanna SCHUITEMAKER, Dan BAROUCH, Jintanat ANANWORANICH, Merlin ROBB, Nelson L. MICHAEL, Jerome KIM